The content on this site is intended for healthcare professionals only
Dr Mathias Rummel talks to ecancer about bendamustine and the changes in standard treatment for lymphoma at the ASCO 2012 Annual Meeting in Chicago, June 2012.
Dr Rummel challenged the current standard, CHOP rituximab, because of its high toxicity and, in some cases, inability to provide a cure.
The treatment used in this clinical trial was combination chemotherapy with bendamustine and rituximab. Progression-free survival was double to nearly six years, compared to the previous standard treatment.
Audio only
Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients
Advancements in paediatric Acute lymphoblastic leukemia management
Choosing 1st line TKI Wisely in patients with CML
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
ATRA-ATO regimen with idarubicin could become the new standard of care in high-risk acute promyelocytic leukaemia
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
Relapsed refractory multiple myeloma
Multiple myeloma (A cancer arising from plasma cells)
